Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase
Peter Sabbatini(GlaxoSmithKline (United States)), Rakesh Kumar(GlaxoSmithKline (United States))
Cited by 79
Related Papers
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
|Molecular Cancer Therapeutics|2009|98
Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A
|The Journal of Cell Biology|2010|59